Results 1 to 10 of about 281,370 (287)

Expression Value of Rab10 in Breast Cancer

Clinical and Experimental Obstetrics & Gynecology, 2023
Background: Rab10 is a small GTPase protein belonging to the Ras superfamily. It is expressed and plays a role in a variety of malignant tumours. However, the expression of Rab10 and its role in breast cancer (BC) prognosis remains unclear.
Jian Zhuo, Yanchun Zhao, Jianjun Han, He Li, Ruiying Hao, Yan Yang, Luxian Dai, Ankang Sheng, Xiaohong Yang, Weiguang Liu   +9 more
doaj   +1 more source

Smoking history and breast cancer risk by pathological subtype: MCC-Spain study

Tobacco Induced Diseases, 2023
Introduction The role of cigarette smoking on breast cancer risk remains controversial, due to its dual carcinogenic-antiestrogenic action. Methods In the population-based multi-case-control study (MCC-Spain), we collected epidemiological and clinical ...
Belén Peñalver-Argüeso, Esther García-Esquinas, Adela Castelló, Nerea Fernández de Larrea-Baz, Gemma Castaño-Vinyals, Pilar Amiano, Tania Fernández-Villa, Marcela Guevara, Guillermo Fernández-Tardón, Juan Alguacil, Mireia Obón-Santacana, Inés Gómez-Acebo, Marina Pinto-Carbó, Rafael Marcos-Gragera, Nuria Aragonés, Amaia Aizpurua, Vicente Martín-Sánchez, Eva Ardanaz, Trinidad Dierssen-Sotos, Jose Juan Jiménez-Moleón, Manolis Kogevinas, Marina Pollán, Beatriz Pérez-Gómez   +22 more
doaj   +1 more source

Effectiveness of EGFR/HER2-targeted drugs is influenced by the downstream interaction shifts of PTPIP51 in HER2-amplified breast cancer cells [PDF]

, 2013
Breast cancer is the most common female cancerous disease and the second most cause of cancer death in women. About 20-30% of these tumors exhibit an amplification of the HER2/ErbB2 receptor, which is coupled to a more aggressive and invasive growth of ...
Brobeil, Alexander, Dietel, Eric, Gattenloehner, Stefan, Tag, Claudia, Wimmer, Monika   +4 more
core   +5 more sources

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. [PDF]

, 2014
IntroductionThe purpose of this study was to retrospectively explore the relationship between human epidermal growth factor receptor 2 (HER2) messenger RNA (mRNA) expression and efficacy in patients receiving trastuzumab plus docetaxel (HT) or ...
Amler, Lukas C, Gianni, Luca, Guardino, Ellie, Hurvitz, Sara A, Mundt, Kirsten E, Ng, Vivian, Perez, Edith A   +6 more
core   +9 more sources

The status of HER2 in colorectal carcinoma and the relation of HER2 with prognostic parameters and MSI

Indian Journal of Pathology and Microbiology, 2022
Background: Colorectal cancer (CRC) is the third most commonly occurring cancer in men and the second most common cancer in women. Despite advances in surgical techniques and chemotherapeutic regimens, CRC continues to be one of the main causes of cancer-
Ismail Saygin, Emel Cakir
doaj   +1 more source

Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer [PDF]

Korean Journal of Clinical Oncology, 2018
Purpose This study aimed to compare the results of treatment with adjuvant trastuzumab for 9 months versus 12 months in human epidermal growth factor 2 (HER2)-positive breast cancer patients. The primary endpoint was disease-free survival.
Ashraf Mahmoud El-Enbaby, Nadia Ahmed Abd El Moneim, Gehan Abd El atti Khedr, Yasmine Mohamed Nagy Elwany   +3 more
doaj   +1 more source

Investigation of Chemical Compounds from Phomopsis Extract as Anti-Breast Cancer Using LC-MS/MS Analysis, Molecular Docking, and Molecular Dynamic Simulations

International Journal of Technology, 2023
Since 2014, we have successfully isolated endophytic fungi from the leaves of Indonesian Annona muricata, exhibiting potential anti-breast cancer properties.
Husnawati, Kusmardi Kusmardi, Rini Kurniasih, AE Zainal Hasan, Dimas Andrianto, Heddy Julistiono, Bambang Pontjo Priosoeryanto, I Made Artika, Mohd Nazil Salleh   +8 more
doaj   +1 more source

Bone metastases of breast cancer: The influence of hormone receptors and human epidermal growth factor receptor 2 [PDF]

Medicinski Podmladak
Breast cancer is the leading cause of cancer-related deaths among women worldwide. While significant progress has been made in the prophylaxis, diagnosis, and management of breast cancer, around 90% of deaths occur due to metastatic disease, which is ...
Rajković Stanislav, Sopta Jelena
doaj   +1 more source

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]

, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
A Goldhirsch, A Hurtado, A Noske, AA Lazar, AC Wolff, Andre Robidoux, BM Müller, Bruno V Sinn, C Denkert, Carsten Denkert, Christine Solbach, CK Osborne, D Slamon, DG Altman, DJ Dabbs, EA Perez, EH Romond, FL Baehner, G Hennig, G Konecny, G Pentheroudakis, G von Minckwitz, G von Minckwitz, G von Minckwitz, Gunter von Minckwitz, H Joensuu, Hans Tesch, I Pinhel, J Baselga, J Baselga, Jan C Brase, Jens Huober, Judith Prinzler, K Bohmann, Keyur Mehta, Knut Engels, L Gianni, L Gianni, LM McShane, M Bonetti, M Dowsett, M Dowsett, M Filipits, M Untch, M Untch, M Untch, M Untch, Martin-Leo Hansmann, Mattea Reinisch, ME Hammond, Michael Untch, MJ Piccart-Gebhart, MP Fereshteh, PC Roche, Peter A Fasching, Ralf Kronenwett, S Johnston, S Paik, S Paik, Sibylle Loibl, Silvia Darb-Esfahani, T Lahusen, W Zhao   +62 more
core   +1 more source

Clinical and molecular characterization of HER2 amplified-pancreatic cancer [PDF]

, 2013
<p>Background: Pancreatic cancer is one of the most lethal and molecularly diverse malignancies. Repurposing of therapeutics that target specific molecular mechanisms in different disease types offers potential for rapid improvements in outcome ...
Biankin, A.V., Chang, D.K., Chantrill, L., Chin, V., Chou, A., Cowley, M.J., Gill, A.J., Goldstein, D., Grimmond, S.M., Humphris, J., Johns, A.L., Kassahn, K.S., Mead, R., Miller, D.K., Morey, A.L., Musgrove, E.A., Nagrial, A.M., Nones, K., Pajic, M., Patch, A.M., Pearson, J.V., Pinese, M., Rooman, I., Samra, J.S., Toon, C.W., Waddell, N., Wasan, H., Wu, J.   +27 more
core   +3 more sources